Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 72.8% in July

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 137,249 shares, a growth of 72.8% from the June 30th total of 79,436 shares. Based on an average daily volume of 165,612 shares, the short-interest ratio is currently 0.8 days. Currently, 11.0% of the shares of the company are short sold.

Aptevo Therapeutics Stock Performance

APVO stock opened at $4.11 on Friday. The company’s 50-day simple moving average is $4.59 and its 200 day simple moving average is $5.47. Aptevo Therapeutics has a 52 week low of $3.68 and a 52 week high of $52.73. The company has a market capitalization of $5.14 million, a PE ratio of -0.02 and a beta of 1.66.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($6.41) EPS for the quarter, hitting analysts’ consensus estimates of ($6.41). On average, analysts forecast that Aptevo Therapeutics will post -23.35 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Aptevo Therapeutics has an average rating of “Hold”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.